TABLE 3.

Effect of Multiple LT-CCCs on Hospital Days in the Last Year of Life for Children With Neuromuscular, Cardiovascular, and Malignancy Conditions

Type and No. of Additional LT-CCCs	Neuromusculara		Cardiovasculara		Malignancya
	Hospital Days	Pb	Hospital Days	Pb	Hospital Days	Pb
Median (IQR) hospital days by no. of LT-CCCs
1 LT-CCC	5 (2–15)	<.001	6 (2–22)	<.001	21 (9–51)	<.001
≥2 LT-CCCs	32 (11–77)		46 (11–112)		75 (31–123)
Effect of additional LT-CCCs on hospital days (SE)c,d
Hematologic/ Immunologic	+58 (7)	<.001	+47 (8)	<.001	+38 (6)	<.001
Gastrointestinal	+50 (9)	<.001	+35 (9)	<.001	+18 (8)	.02
Metabolic	+42 (4)	<.001	+36 (5)	<.001	+33 (5)	<.001
Renal	+40 (8)	<.001	+27 (9)	<.01	+13 (9)	.2
Malignancy	+36 (5)	<.001	+29 (6)	<.001	NAe	NA
Respiratory	+32 (6)	<.001	+22 (7)	<.01	+3 (9)	.8
Cardiovascular	+17 (4)	<.001	NAe	NA	−9 (6)	.1
Congenital/ Genetic	+5 (4)	.2	−6 (4)	.1	−22 (7)	<.001
Neuromuscular	NAe	NA	−8 (4)	.03	−29 (5)	<.001

NA, not applicable.

^aNeuromuscular, cardiovascular, and malignancy were selected for presentation because they are the 3 most prevalent conditions among children in the cohort.

^bP values were obtained from a type III block test on the fixed effect of interest (eg, type of LT-CCC) that was included in generalized linear models; statistical significance is defined as a P value of < .05.

^cShown are greater (+) or fewer (−) hospital days with SE experienced in the presence of a specific additional LT-CCC. For example, among children with a neuromuscular LT-CCC, the presence of an additional hematologic/immunologic LT-CCC added 58 (SE 7) hospital days in the last year of life. Hospital days and SE were estimated from generalized linear models.

^dLT-CCCs are ranked in order from greatest to least added hospital days for children with neuromuscular conditions.

^eNot applicable, as every child in the cohort of interest has this condition.